| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
Form 4: Drinane Juliana Papa, Head of Mfg & Supply
Received 3,626 shares by exercise or conversion · Gave up 1,242 shares to cover exercise price or tax ($17.2K) |
| 10 Nov 2026 |
Form 4: Arjona Ferreira Juan Camilo, Head of R&D & CMO
Received 6,447 shares by exercise or conversion · Gave up 2,314 shares to cover exercise price or tax ($32.1K) |
| 10 Nov 2026 |
Form 4: Holzbaur Lynette, SVP and Corporate Controller
Received 3,038 shares by exercise or conversion · Gave up 866 shares to cover exercise price or tax ($12K) · Received 2,418 shares by exercise or conversion · 1 more |
| 30 Oct 2026 |
8-K: Regulation FD Disclosure
This exhibit provides certain supplemental non-GAAP financial measures for the quarter ended September 30, 2026. As disclosed in the accompanying Current Report on Form 8-K, Organon & Co. (the “Company”) is furnishing this information in... |
| 30 Oct 2026 | 10-Q |
| 14 Aug 2026 | SCHEDULE 13G |
| 12 Aug 2026 |
Form 4: Arjona Ferreira Juan Camilo, Head of R&D & CMO
Received 11,519 shares by exercise or conversion · Gave up 4,134 shares to cover exercise price or tax ($56.3K) · Acquired 11,519 Restricted Stock Units (Option Exercise/Conversion) |
| 05 Aug 2026 | 144 |
| 05 Aug 2026 |
Form 4: Drinane Juliana Papa, Head of Mfg & Supply
Sold 14,761 shares ($200K) |
| 31 Jul 2026 | SCHEDULE 13G/A |
| 31 Jul 2026 |
8-K: Regulation FD Disclosure
This exhibit provides certain supplemental non-GAAP financial measures for the quarter ended June 30, 2026. As disclosed in the accompanying Current Report on Form 8-K, Organon & Co. (the “Company”) is furnishing this information in lieu... |
| 31 Jul 2026 | 10-Q |
| 23 Jul 2026 |
8-K: Submission of Matters to a Vote of Security Holders
A special meeting of stockholders (the “Special Meeting”) of Organon & Co., a Delaware corporation (the “Company”), was held on July 23, 2026 at 10:00 a.m., Eastern Time, via a virtual meeting website. The Special Meeting was held in ord... |
| 17 Jul 2026 | DEFA14A |
| 17 Jul 2026 |
8-K: Other Events
As previously disclosed, on April 26, 2026, Organon & Co., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Sun Pharmaceutical Holdings USA, Inc. (“Su... |
| 17 Jun 2026 | DEFM14A |
| 15 Jun 2026 |
Form 4: Sharp Shalini, Director
Granted 17,857.143 Phantom Stock ($240K) |
| 15 Jun 2026 |
Form 4: Sequeira Ramona, Director
Granted 17,857.143 Phantom Stock ($240K) |
| 15 Jun 2026 |
Form 4: Patton Cynthia M, Director
Granted 17,857.143 Phantom Stock ($240K) |
| 15 Jun 2026 |
Form 4: Ozuah Philip, Director
Granted 17,857.143 Phantom Stock ($240K) |
Loading...